A bond you can count on
We are a CRO based at the heart of the Barcelona Science Park. With more than 20 years of experience in chemistry services, we provide contract research and development services in Medicinal Chemistry, Chemical R&D and Solid State R&D.
Contact us to find out how our expertise in Cocrystals and Asymmetric Synthesis can help your project succeed, now also for Highly Potent Compounds too.
A bond you can count on
We are a CRO based at the heart of the Barcelona Science Park. We specialise in Medicinal Chemistry, Chemical R&D and Solid State R&D.
Contact us to find out how our expertise in Cocrystals and Asymmetric Synthesis can help your project succeed, now also for High Potent Compounds too.
Our Medicinal Chemistry team has a solid background in the design and synthesis of small molecules as ligands for a broad range of therapeutic targets.
We can contribute in the different stages of your drug discovery program.
Chemistry that works. We work in the resolution of chemical challenges, the design of new routes of synthesis and their impurity profiling, resulting in the creation of valuable processes for fine chemical, pharma and biotech industry.
Crystallising your ideas. We can help you through the entire process of solid form selection, from the initial screening, analysis, characterisation and performance tests, to its development, scale-up and long-time stability tests.
2024 Flow Chemistry
New flow chemistry capacities at EnantiaFlow chemistry is now available at Enantia for medicinal chemistry and CMC development services.
This will complement our 20 years of experience in batch and semi-batch chemistry to develop sustainable, safe and efficient chemical processes.
Enantia celebrates 20 years of excellence in chemical services
Enantia is commemorating its 20th anniversary this year, marking two decades of dedication to excellence in chemistry and innovation.
Since our inception in 2003, Enantia has been providing cutting-edge solutions to the pharmaceutical, biotech, and material industries by offering a comprehensive suite of services encompassing medicinal chemistry, CMC development, solid form R&D, and more.
Licensing of Esteve and Mundipharma
An innovative cocrystal, obtained by Enantia working in collaboration with Esteve R&D, is part of the global partnership announced by Esteve and Mundipharma-Purdue.
Collaboration with the ALBA Synchrotron light
Start of the ALBA synchrotron collaboration, the most important light facility in the south of Europe.
Since 2014, here at Enantia we have taken advantage of the ALBA’s light beam, allowing us to reach even higher resolution and greater sensitivity. With the in house diffractometer we are already able to characterise a crystaline structure, however with the ALBA beamline we are able to tackle the most challenging projects.
The same year we celebrated filing our 40 th patent.
European consortium Nano3Bio
Enantia enters in the Nano3Bio’s international scientific project in the field of biotechnology. Its goal is the breakthrough from basic research to biotechnological production of chitosans. The consortium represents eight countries (six universities, two research centres, 13 start-up or well established SMEs and one large company).
Senén Vilaró Prize
The company is awarded the 2011 Senén Vilaró Prize. The Bosch i Gimpera Foundation (University of Barcelona) gives this prize as a recognition of Enantia’s track record in transferring its scientific and technical knowledge back to society.
Enantia, selected by Neogenius as preferred partner
Set up on the basis of a strategic alliance between four pharmaceutical companies (Almirall, Esteve, Palau Pharma and Proteomika), the Neogenius project kicks off and runs for four years with a total budget of 15.4 million euros with the objective to discover and develop new painkilling medicines for patients suffering from osteoarthritis.
Enantia is selected as custom synthesis provider to support the drug discovery activities of the consortium.
Pimec Prize for the most competitive company
Enantia is awarded the 2008 Pimec Prize (Premis Pimec) for the most competitive small company. This prize was given personally by the King of Spain Juan Carlos I to the then CEO Llorenç Rafecas during a dinner in Barcelona. Pimec is the association that represents the micro, small and medium-sized companies in Catalonia.
CENIT R&D project
Genius Pharma, a consortium led by the three major Spanish pharmaceutical companies in which Enantia plays one of the leading roles, wins a CENIT R&D project (CDTI). The main objective of the project is to develop, build and exploit technology platforms and best practices in the drug discovery process.
Success in tech transfer
Enantia is created as a spin-off of the University of Barcelona with headquarters in the Barcelona Science Park. The initial team is composed of eight people including Mr. Llorenç Rafecas as CEO, a professional with 24 years of experience in the fine chemicals industry, with executive responsibilities in chemical R&D.